Alzheimer's Diseases
Alzheimer’s disease is a progressive brain disorder that gradually erodes memory, thinking skills, and the ability to carry out simple tasks. It’s the most common form of dementia.
Symptoms of Alzheimer’s Disease slowly worsen over time. Early signs include Memory loss, challenges with familiar tasks, Problems with language, mood changes, disorientation and personality changes.
The Paradox of Alzheimer's: Rising Cases, Stagnant Trials
A Strategic Approach
Fyzil Globals’ focus on both patients and caregivers is a commendable strategy. By doing so, addressing a critical gap in Alzheimer’s research and care. This provides improved participation in clinical enrollment and then, improved patient outcomes.
Typically, Alzheimer’s disease affects people aged 65 and older, although some cases occur earlier. We assist both patients with Alzheimer’s at all stages of the disease and their caregivers. Our focus is on individuals most likely to develop Alzheimer’s.
Digital technologies, such as wearables and sensors, are revolutionizing Alzheimer’s disease research by providing continuous, real-world data on patient cognition and function. This data helps identify suitable patients earlier, track disease progression more accurately, and improve treatment evaluation. These technologies also enhance patient care and safety.
We specialize in implementing these digital solutions in clinical trials. Our expertise includes navigating regulations, educating patients and caregivers, and providing comprehensive support to research sites. Leveraging our experience in hybrid and decentralized trials, we can optimize your study design and execution.
We are dedicated to facilitating groundbreaking discoveries, improving patient outcomes, and advancing clinical research solutions.
